CVS Health price target raised to $100 from $95 at BofA

BofA raised the firm’s price target on CVS Health (CVS) to $100 from $95 and keeps a Buy rating on the shares after the company reported a Q1 beat with revenue, EBIT, and EPS above consensus expectations. The firm views GLP-1 rebate guarantees as the biggest risk to the CVS upside revision story, but adds that the continued execution across all other business lines – including Aetna, pharmacy, and Oak Street – gives it “confidence the upside revision story can continue.”